Azab, M., Mohamed, E. (2022). Study of the Effect of Glycated Albumin Compared to Glycated Hemoglobin as An Indicator of Blood Glucose in Haemodialysis Patients Suffering from Diabetes Mellitus. The Egyptian Journal of Hospital Medicine, 89(2), 7189-7194. doi: 10.21608/ejhm.2022.273063
Mina Misheal Welson Azab; Essam Abdelmohsen Mohamed. "Study of the Effect of Glycated Albumin Compared to Glycated Hemoglobin as An Indicator of Blood Glucose in Haemodialysis Patients Suffering from Diabetes Mellitus". The Egyptian Journal of Hospital Medicine, 89, 2, 2022, 7189-7194. doi: 10.21608/ejhm.2022.273063
Azab, M., Mohamed, E. (2022). 'Study of the Effect of Glycated Albumin Compared to Glycated Hemoglobin as An Indicator of Blood Glucose in Haemodialysis Patients Suffering from Diabetes Mellitus', The Egyptian Journal of Hospital Medicine, 89(2), pp. 7189-7194. doi: 10.21608/ejhm.2022.273063
Azab, M., Mohamed, E. Study of the Effect of Glycated Albumin Compared to Glycated Hemoglobin as An Indicator of Blood Glucose in Haemodialysis Patients Suffering from Diabetes Mellitus. The Egyptian Journal of Hospital Medicine, 2022; 89(2): 7189-7194. doi: 10.21608/ejhm.2022.273063
Study of the Effect of Glycated Albumin Compared to Glycated Hemoglobin as An Indicator of Blood Glucose in Haemodialysis Patients Suffering from Diabetes Mellitus
Background: The prognosis of individuals with diabetes mellitus (DM) and chronic renal disease who get regular hemodialysis (HD) is improved by strict glycemic management. Glycated haemoglobin (HbA1c) may not be a useful test for glycemic management in certain patients. Objective: We aimed to assess the efficacy of glycated albumin (GA) versus HbA1c, as a glycemic control indicator, in diabetic patients on HD. Patients and methods: In between 2016 and 2017; a total of 75 subjects were included in the study. Participants were divided into 3 groups: Group 1; diabetic patients on HD (n=50), Group 2; diabetics with normal renal function (n=10) and Group 3; control group (n=15). Through history and clinical evaluation was performed. GA and HbA1c were done in all groups. Results: diabetic patients on HD had significantly higher GA, while HbA1c was significantly higher in those diabetic patients with normal renal function. GA had 87.1% sensitivity and 72.73% specificity at a cutoff point >31% for prediction of uncontrolled DM in those patients on regular HD while HbA1c had 72% sensitivity and 73% specificity at a cutoff point >6.7%. GA had 67% sensitivity and 85% specificity at a cutoff point >27% for prediction of uncontrolled DM in those patients with normal renal function, while HbA1c had 67% sensitivity and 71% specificity at a cutoff point >7.9%. Conclusion: Glycated albumin could be used as an indicator for glycaemic control in patients on regular HD. Future studies are warranted to confirm such findings.